未知生产厂商
ATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.
ATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.
ATG003 acts by inhibiting the angiogenic pathway mediated by the nicotinic acetylcholine receptors found on endothelial cells (EC-NAChR). Inhibiting this pathway also inhibits the synthesis and cellular responses mediated by growth factors such as VEGF and bFGF.
Investigated for use/treatment in macular degeneration.
